spacer
home > ebr > Winter 2014
PUBLICATIONS

European Biopharmaceutical Review

ebr
Winter 2014

   
Text
PDF
Editor’s Letter

Deborah O’Neil reviews how regulations can assist with safer therapies, and explores some of this issue’s focus features.
 
view
download pdf
Science and Innovation
Monitoring Aggregation

Characterisation Techniques


Therapeutic protein molecules are prone to degradation in the body if their binding efficacy is lost, but Pauline Carnell and Sarah Newell at NanoSight Ltd suggest that a new technique may provide the solution.
 
view
download pdf
bullet
BioBusiness Development
Strategy and Finance

Rising Up: Part 2


In the second of a two-part series, Graham Scholefield and Markus Thunecke at Catenion explore new strategies to integrate payer needs with R&D decision-making.
 
view
download pdf
bullet
BioResearch and Innovation
Antimicrobial Therapeutics

First Class


Vanessa Duncan, Douglas Fraser-Pitt and Derry Mercer at NovaBiotics Ltd review how peptide anti-infectives are offering a different approach to the therapeutic field.
 
view
download pdf
bullet
Discovery Technology
NMR-Based Methods

Data Streaming


A new tool for optimising cell feed strategy and upstream process development has been unveiled. Nuclear magnetic resonance technology is successfully improving Quality by Design data, says Frederic Girard at Spinnovation Biologics.
 
view
download pdf
bullet
Drug Discovery
Phenotypic Drug Discovery

Target Practice


Target deconvolution using phenotypic screening methods is beginning to provide greater opportunities for the development pipeline. Jim Freeth at Retrogenix explains how this could help to produce many new and innovative drugs.
 
view
download pdf
Drug Discovery

Data Mine


Pooja Jain at PharmaPendium reports on how the amount of data generated by the industry is outweighing the information management strategies that are already in place.
 
view
download pdf
bullet
CANCER FOCUS
Oncology Approvals

Cancer Concerns


Vijaya Vulapalli
at GBI Research discusses the many challenges that the oncology sector faces. Inaccessible treatments, high costs and increasing death rates are just a few of the obstacles that need to be tackled.
 
view
download pdf
Cancer Diagnostics

Making a Mark


Alfred Hansel and Martina Schmitz at oncgnostics GmbH explore how DNA methylation-based epigenetic markers are demonstrating their vast diagnostic potential for in vitro testing.
 
view
download pdf
bullet
APPLIED RESEARCH, DEVELOPMENT AND PRODUCTION
Bioprocess Monitoring

Real-Time Approach


The complexity of using living cells as production systems represents a major challenge in bioprocess design and control. Markus Luchner, Timo Schmidberger and Gerald Striedner at ACIB highlight how proton transfer reaction mass spectrometers hold the potential to change this.
 
view
download pdf
bullet
REGIONAL UPDATES
Bioregional

Investing in the Future


Uldouz Berenjforoush at Frost & Sullivan examines why Azerbaijan is becoming an attractive destination for new investors, as their expanding economy and plans to develop primary care come to the forefront.
 
view
download pdf
bullet
INTERVIEW
Industry Interview

Business Speak


Dr Jean-Pierre Wery, President of Crown Bioscience, speaks to EBR to discuss his business philosophy, share his goals for the coming year, and reveal the secret of his success.
 
view
download pdf
bullet
DEVELOPMENT AND PRODUCTION
Molecular Treatments

mRNA: Get the Message


Ingmar Hoerr at CureVac reveals how messenger ribonucleic acids are beginning to transform modern molecular medicine as a novel therapeutic class.
 
view
download pdf
bullet
MARKETPLACE
Proof of Concept

Adding Value


Pinar Akpinar, Cyril Clarke and Nigel Gregson illustrate how proof-of-concept and proof-of-value are linked when bringing a new drug to market.
 
view
download pdf
In Brief

Return of the Blockbuster?


Against the popular consensus of industry leaders, Emile Bellott considers whether the emphasis on niche indications is over as the blockbuster era makes a comeback.
 
view
download pdf
bullet
BIO-SECURITY
Bio-Security

Pipeline of Terror


Boaz Ganor, Miri Halpern Wernli and Mollie Shields Uehling at Actelion debate the threat of terrorism to the biopharmaceutical industry. What can the industry do to protect itself?
 
view
download pdf
bullet
BIOIMAGING
Four-Dimensional Imaging

A Deadly Bite


Dr Bülent Peker at Olympus Europa demonstrates how four-dimensional imaging could tackle the complex blood stage of the malarial pathogen Plasmodium falciparum.
 
view
download pdf
Image Processing Techniques

Marked Data


More sophisticated image analysis techniques would allow for greater optimisation of biomarker data. Andrew J Buckler and James C Keith at Elucid Bioimaging Inc explain the advantages that this could bring.


 
view
download pdf
   
spacer
Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July and October

News and Press Releases

New awareness campaign aims to help organisations prepare for GS1


More info >>

White Papers

Bio/Pharmaceutical Methods: Do your Analytical Methods Hold Up to Regulatory Scrutiny?

Eurofins BioPharma Product Testing

As FDA guidelines evolve and drug products on the market begin to age, bio/pharmaceutical manufacturers face scrutiny of the original methods used to support these products. Therefore, manufacturers must re-evaluate these methods to ensure they comply with current FDA expectations. Some manufacturers are even facing consent decrees imposed by the agency requiring them to bring methods up to current standards within a specified timeframe. This exercise requires significant amounts of time and resources, which many manufacturers do not have since they are focused on getting their next products to market. For that reason, some clients have been turning to Eurofins Lancaster Laboratories for support.
More info >>

Industry Events

6th Annual Cancer Vaccines Conference

27-28 September 2017, Copthorne Tara Hotel, London UK

Cancer Vaccines 2017: Overcoming hurdles to cancer immune response: Cell therapies, vaccine development and combination therapies. SMi Group is thrilled to present the 6th annual Cancer Vaccines conference, taking place on 27th & 28th September 2017 in Central London, UK. Overcoming hurdles to cancer immune response: Cell therapies, vaccine development and combination therapies.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement